The READDI-AViDD Center, one of nine established by the NIH, is an integrated public-private partnership with a renowned, interdisciplinary research team of experts from the Gillings School, UNC School of Medicine and UNC Eshelman School of Pharmacy.
READDI, in Collaboration with Chimerix, to Present at International Conference on Antiviral Research
Preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research (ICAR) on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT. CMX521 was found to significantly reduce lung viral titer and clinical symptoms in a SARS-CoV-2 mouse model.
The state funds will allow READDI to build out a small management team, including the initial hire of a CEO, who will work to create broad spectrum antiviral drugs to combat novel coronaviruses, among other viruses.
READDI was selected from among 136 applications to receive the award, aimed at accelerating the production of antiviral drugs.
READDI will be featured in "The Health of Our State and Beyond Series" at University of North Carolina's annual University Research Week.
SAS joins Rapidly Emerging Antiviral Drug Development Initiative to advance drug discovery with artificial intelligence and machine learning.
READDI is among eight projects selected to advance from 136 proposals initially submitted.
We have a bounty of vaccines and more on the way, but drugs that treat the disease are vital too if we want to keep people alive and bring the pandemic under control.
With few good targets and limited financial incentives, the field of antiviral drug discovery has lagged. The COVID-19 pandemic might be awakening the world to the problem.
Boris Johnson wants to do for Covid drugs what he did for vaccines. It’s not that simple.